This report describes and analyses the Global Alliance to Eliminate Lymphatic Filariasis (GAELF), a Global Public-Private Initiative (GPPIs) for health. This report focuses on the role of pharmaceutical industry partners in the operations and governance of the GAELF. It does not evaluate outcomes or effectiveness in much detail, nor does it provide an analysis of each company’s approach to GPPIs for healthcare in general. This report forms part of a broader research project on the role of companies in public-private partnerships. Field studies on the implementation of the GPPIs in developing countries, conducted by partner organizations of WEMOS, form part of the broader research project.